EFG Asset Management (Americas)’s Legend Biotech LEGN Stock Holding History

EFG Asset Management (Americas)’s Portfolio LEGN Stock Details LEGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-4,641	Closed	-$279K	–	134
2023 Q4	$279K	Sell	4,641 -1,548	-25%	-$98.1K	0.06%	132
2023 Q3	$416K	Sell	6,189 -645	-9%	-$44.8K	0.1%	113
2023 Q2	$472K	Sell	6,834 -1,779	-21%	-$116K	0.11%	109
2023 Q1	$415K	Buy	8,613 +1,475	+21%	+$72.1K	0.1%	109
2022 Q4	$356K	Buy	7,138 +575	+9%	+$27.9K	0.09%	109
2022 Q3	$268K	Hold	6,563	–	–	0.07%	122
2022 Q2	$361K	Sell	6,563 -1,175	-15%	-$49.6K	0.09%	110
2022 Q1	$281K	Buy	7,738 +2,727	+54%	+$108K	0.05%	125
2021 Q4	$234K	Buy	+5,011	New	+$254K	0.04%	130

Other funds holding LEGN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

EFG Asset Management (Americas)'s LEGN Position: Q1 2024 in Review

EFG Asset Management (Americas) sold out of Legend Biotech (LEGN) in Q1 2024, closing a stake of 4,641 shares — an estimated $279K sold.

EFG Asset Management (Americas) first reported a position in LEGN in Q4 2021 and held it in 9 quarters. The position peaked at $472K in Q2 2023. 192 funds tracked by Wall St. Rank hold LEGN as of Q1 2024.

EFG Asset Management (Americas) reported no remaining Legend Biotech position as of Q1 2024 after selling out during the quarter.
EFG Asset Management (Americas) sold 4,641 Legend Biotech shares in Q1 2024, an estimated $279K.
EFG Asset Management (Americas) first reported a position in Legend Biotech in Q4 2021 and held it in 9 quarters.
EFG Asset Management (Americas)'s Legend Biotech position peaked at $472K in Q2 2023.
192 funds tracked by Wall St. Rank held Legend Biotech as of Q1 2024.

Based on EFG Asset Management (Americas)'s 13F filing for Q1 2024, filed 22 Apr 2024.